Swedish clinical-stage pharmaceutical company Vicore Pharma Holding AB (STO:VICO) announced on Friday an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku Co Ltd, granting rights for the development and commercialisation of Vicore's drug candidate C21 in Japan.
Vicore will receive an upfront payment of USD10m and stands to gain up to USD275m in milestone payments, along with tiered royalty payments.
Nippon Shinyaku will initially focus on developing C21 for idiopathic pulmonary fibrosis (IPF), aiming to address the limited treatment options for approximately 34,000 patients in Japan.
Vicore retains all rights to C21 outside of Japan.
C21, an oral therapy, has shown promising results in stabilising or improving lung function in IPF patients. A global Phase 2b ASPIRE study is planned to begin in the first half of this year.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration